165 related articles for article (PubMed ID: 9814695)
21. Expression of apoptosis in placenta of experimental antiphospholipid syndrome mouse.
Velayuthaprabhu S; Matsubayashi H; Sugi T; Nakamura M; Ohnishi Y; Ogura T; Archunan G
Am J Reprod Immunol; 2013 May; 69(5):486-94. PubMed ID: 23398188
[TBL] [Abstract][Full Text] [Related]
22. Anti-cardiolipin antibody from a patient with antiphospholipid syndrome (APS) recognizes only an epitope expressed by cardiolipin/beta 2-glycoprotein-I (beta 2GPI) complex and induces APS.
Levy Y; Sherer Y; Mathieu A; Cauli A; Passiu G; Sanna G; Janackovic Z; Blank M; Shoenfeld Y
Clin Exp Rheumatol; 2000; 18(4):479-84. PubMed ID: 10949723
[TBL] [Abstract][Full Text] [Related]
23. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome.
von Scheven E; Glidden DV; Elder ME
Arthritis Rheum; 2002 Aug; 47(4):414-20. PubMed ID: 12209489
[TBL] [Abstract][Full Text] [Related]
24. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome.
Krause I; Blank M; Fraser A; Lorber M; Stojanovich L; Rovensky J; Shoenfeld Y
Immunobiology; 2005; 210(10):749-54. PubMed ID: 16325493
[TBL] [Abstract][Full Text] [Related]
25. Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype.
Pierangeli SS; Espinola R; Liu X; Harris EN; Salmon JE
Arthritis Rheum; 2001 Apr; 44(4):876-83. PubMed ID: 11315927
[TBL] [Abstract][Full Text] [Related]
26. Anti-phospholipid syndrome: from patient's bedside to experimental animal models and back to the patient's bedside.
Ziporen L; Shoenfeld Y
Hematol Cell Ther; 1998 Oct; 40(5):175-82. PubMed ID: 9844811
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome.
Katzav A; Kloog Y; Korczyn AD; Molina V; Blank M; Shoenfeld Y; Chapman J
Immunobiology; 2003; 207(1):47-50. PubMed ID: 12638903
[TBL] [Abstract][Full Text] [Related]
28. Antiphospholipid antibodies, antiphospholipid syndrome and infections.
Sène D; Piette JC; Cacoub P
Autoimmun Rev; 2008 Feb; 7(4):272-7. PubMed ID: 18295729
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome.
George J; Blank M; Levy Y; Meroni P; Damianovich M; Tincani A; Shoenfeld Y
Circulation; 1998 Mar; 97(9):900-6. PubMed ID: 9521339
[TBL] [Abstract][Full Text] [Related]
30. Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with beta 2 GPI.
García CO; Kanbour-Shakir A; Tang H; Molina JF; Espinoza LR; Gharavi AE
Am J Reprod Immunol; 1997 Jan; 37(1):118-24. PubMed ID: 9138445
[TBL] [Abstract][Full Text] [Related]
31. The heart and antiphospholipid antibodies in MRL-lpr/lpr mice.
Vianna JL; Trotter S; Khamashta MA; Chikte S; Olsen E; Hughes GR
Lupus; 1992 Dec; 1(6):357-61. PubMed ID: 1304403
[TBL] [Abstract][Full Text] [Related]
32. [Antiphospholipid syndrome].
Yuste JR; Beloqui O; De la Peña A; Prieto J
Rev Med Univ Navarra; 1998; 42(4):194-207. PubMed ID: 10420931
[TBL] [Abstract][Full Text] [Related]
33. Anticardiolipin and anti-beta-2-glycoprotein I antibodies.
Marai I; Tincani A; Balestrieri G; Shoenfeld Y
Autoimmunity; 2005 Feb; 38(1):33-8. PubMed ID: 15804703
[TBL] [Abstract][Full Text] [Related]
34. [Clinical significance of antiphospholipid antibodies].
Atsumi T; Koike T
Rinsho Byori; 1998 Apr; 46(4):297-302. PubMed ID: 9594618
[TBL] [Abstract][Full Text] [Related]
35. Experimental models for antiphospholipid studies.
Gharavi AE; Aron AL
Haemostasis; 1994; 24(3):204-7. PubMed ID: 7988949
[TBL] [Abstract][Full Text] [Related]
36. Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome.
Meneghel L; Ruffatti A; Gavasso S; Tonello M; Mattia E; Spiezia L; Tormene D; Hoxha A; Fedrigo M; Simioni P
Clin Chim Acta; 2015 Jun; 446():201-5. PubMed ID: 25935129
[TBL] [Abstract][Full Text] [Related]
37. Oral tolerance to low dose beta 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome.
Blank M; George J; Barak V; Tincani A; Koike T; Shoenfeld Y
J Immunol; 1998 Nov; 161(10):5303-12. PubMed ID: 9820503
[TBL] [Abstract][Full Text] [Related]
38. Early onset of autoimmunity in MRL/++ mice following immunization with beta 2 glycoprotein I.
Aron AL; Cuellar ML; Brey RL; Mckeown S; Espinoza LR; Shoenfeld Y; Gharavi AE
Clin Exp Immunol; 1995 Jul; 101(1):78-81. PubMed ID: 7621596
[TBL] [Abstract][Full Text] [Related]
39. Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome.
Katzav A; Litvinjuk Y; Pick CG; Blank M; Shoenfeld Y; Sirota P; Chapman J
Behav Brain Res; 2006 May; 169(2):289-93. PubMed ID: 16530276
[TBL] [Abstract][Full Text] [Related]
40. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
Cabiedes J; Cabral AR; Alarcón-Segovia D
J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
